The global biotherapeutics cell line development market
is characterized by a largely consolidated landscape, as the top two
players held a sizeable share of 85% of the global market in 2015, finds
Transparency Market Research (TMR). These companies are Beckman Coulter
and Becton Dickinson and Company. The combined massive share held by
these players is increasingly inhibiting the entry of new players, for
whom the merger may be a potential option for getting a foothold in the
market. The significant clout that leading players hold in the market
accounts for the plethora of avenues to organically boost their
expansion and consolidate their shares. TMR observes that over the
years, several emerging and new entrants are likely to focus on new
product developments and technological innovations to get a better
foothold in the market.
Some of the other prominent players
operating in the market include Thermo Fisher Scientific Inc., ProBioGen
AG, Boehringer Ingelheim, Sony Biotechnology Inc., Sysmex Partec GmbH,
Lonza Group Ltd., CMC Biologics, Catalent Inc., and Beckman Coulter.
The global biotherapeutics cell line
development market stood at US$56 million in 2014 and is projected to
touch a valuation of approximately US$100 million by the end of 2022.
The market is prognosticated to expand at 7.50% CAGR in between the
forecast period from 2015 to 2022.
The main processes of biotherapeutics
cell line development comprise transfection and selection and single
cell cloning. Of the two, the former led the majority of the share by a
huge margin in 2015. This can be attributed to the extensive application
of the various methods of single cell cloning in proving the
monoclonality during cell line development.
Regionally, Asia Pacific is projected to
emerge as the potentially attractive market rising at a promisingly
higher CAGR pegged at 9.40% during 2015–2022. The colossal untapped
medical needs is key to the rapid rise of the regional revenue.
Promising Potential of Biological Therapeutics in Treating Chronic Diseases and various Cancer Types
The growing significance of biological
therapeutics in treating a range of chronic diseases, notably diabetes
and arthritis, and various cancer types is a primary factor catalyzing
the growth of the biotherapeutics cell line development market. The
growing number of protein-based therapeutics either approved or in
developmental phases in various parts of the globe is bolstering the
demand for biotherapeutics cell line development. Moreover, the advent
of high-expressing cell lines is further boosting the market.
The rising incidence of chronic diseases
world over and a rapidly rising geriatric population in developing and
developed countries are significant factors helping in the substantial
expansion of the global market. Unlike small molecules, biotherapeutics
has proved to be potentially promising in managing diseases such as
cancer, diabetes, multiple sclerosis, and a wide range of degenerative
diseases.
Stringent Regulatory Framework Impedes Market in Realizing Full Potential
Considerable efforts to launch
biopharmaceutical drugs, especially in developed regions, are likely to
propel the growth of the biotherapeutics cell line development market. A
burgeoning research funds committed by several biopharmaceutical
companies in emerging economies in the development of these drugs is
supporting the global market’s expansion. Numerous strict regulatory
framework encompassing various cell culture procedures have dampened new
entrants and emerging players. This is hampering the market’s growth.
This is especially evident in stable cell line producing biologics.
Nevertheless, vast unmet medical needs in
several developing regions of the globe will pave way for exciting
avenues for market players. The market will also gain tremendous
momentum from the substantially rising for antibody-related products.
